﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Health Promotion Perspectives</JournalTitle>
      <Issn>2228-6497</Issn>
      <Volume>2</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2012</Year>
        <Month>12</Month>
        <DAY>31</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Benefits of Omega-3 Fatty Acids Supplementation on Serum Paraoxonase 1 Activity and Lipids Ratios in Polycystic Ovary Syndrome</ArticleTitle>
    <FirstPage>197</FirstPage>
    <LastPage>204</LastPage>
    <ELocationID EIdType="doi">10.5681/hpp.2012.023</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Elahe</FirstName>
        <LastName>Mohammadi</LastName>
      </Author>
      <Author>
        <FirstName>Maryam</FirstName>
        <LastName>Rafraf</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.5681/hpp.2012.023</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2012</Year>
        <Month>02</Month>
        <Day>29</Day>
      </PubDate>
    </History>
    <Abstract>Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with increased risk of cardiovascular disease. The purpose of this study was to investigate the effects of omega-3 fatty acids on serum paraoxonase 1 activity and lipids ratios in polycystic ovary syndrome. Methods: This double-blind randomized controlled clinical trial was conducted on 64 PCOS patients with 20-35 years old. Thirty two of the subjects had taken 4 g/day omega -3 fatty acids and 32 patients were given placebo for 8 weeks. Fasting blood samples, anthropometric measurements and dietary intakes were collected at the beginning and the end of the study. Serum total cholesterol, triglyceride, and HDL-C were measured using the enzymatic methods. LDL-C con¬centration was calculated by the Friedewald formula and arylesterase activity of serum PON1 was measured. Data were analyzed using SPSS software. Results: Omega-3 fatty acids significantly decreased TC/HDL-C and LDL-C/HDL-C ratios (P = 0.009 for both) and significantly increased serum PON1 activity (P = 0.048) compared with placebo. Changes in TG/HDL-C ratio were not statistically significant in omega-3 fatty acids group at the end of the study in comparison to placebo group. Reduction in TC/HDL-C, LDL-C/HDL-C and TG/HDL-C ratios and increase in serum PON1 activity were also significant in omega-3 fatty acids group at the end of the study compared with baseline values (P &lt;0.001, P &lt; 0.001, P = 0.004, and P = 0.001, respectively). Conclusion: Omega-3 fatty acids may decrease the risk for cardiovascular disease through the improvement in paraxonase-1 activity and reduction in some lipids ratio in PCOS women.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Omega-3 fatty acids</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Polycystic ovary syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Paraoxonase 1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lipids</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>